Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European‐Americans and Egyptians. Issue 1 (19th January 2016)

• Record Type: Journal Article
• Authors: Hamadeh, IS; Shahin, MH; Lima, SM; Oliveira, F; Wilson, L; Khalifa, SI; Langaee, TY; Cooper‐DeHoff, RM; Cavallari, LH; Johnson, JA
• Is Part Of: Clinical and translational science. Volume 9:Issue 1(2016)
• Page Start: 36
• Page End: 42
• Publication Date: 2016-01-19
• Subjects: Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; 616.027
• DOI: 10.1111/cts.12385
• Languages: English
• ISSNs: 1752-8054

Abstract

Abstract : Genotype‐based algorithms that include VKORC1 and CYP2C9 genotypes are less predictive of warfarin dose variability in Africans as opposed to Europeans. Polymorphisms in GGCX, FPGS, or STX1B are associated with warfarin dose requirements in African‐Americans. We sought to determine if they influenced warfarin dose in European‐Americans, and another African population, specifically Egyptians. We genotyped 529 adults ( n = 325 European‐Americans, 204 Egyptians) on a stable warfarin dose for GGCX rs12714145 and rs10654848, FPGS rs7856096, and STX1B rs4889606. Rs12714145, rs10654848, and rs7856096 were not associated with warfarin dose, whereas STX1B rs4889606 was a significant determinant in univariate analysis ( P < 0.0001) in both cohorts. However, STX1B rs4889606 was in high linkage disequilibrium with VKORC1 ‐1639 G>A, and was no longer significant after including VKORC1 ‐1639 G>A in the regression model. Based on these data, the polymorphisms do not appear to influence, in a clinically important way, warfarin dose requirements in European‐Americans and Egyptians.